TSTatsuya Sawamura

Tatsuya Sawamura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tatsuya Sawamura has a total of 175 co-authors. Here are the top co-authors by number of shared publications:

  • Akemi Kakino

    Department of Molecular Pathophysiology, School of Medicine, Shinshu University , Matsumoto, Nagano 390-8621 , Japan

    15 shared publications
  • Yoshiko Fujita

    Shinshu University, Japan

    14 shared publications
  • Ryo Yoshimoto

    Department of Vascular Physiology , National Cerebral and Cardiovascular Center Research Institute, Suita, Osaka, Japan

    5 shared publications
  • Yuko Sato

    Cell Biology Center, Institute of Innovative Research, Tokyo Institute of Technology, Yokohama, Japan

    5 shared publications
  • Atushi Nakano

    National Cerebral and Cardiovascular Center Research Institute

    4 shared publications
  • Kazunori Otsui

    Department of Vascular Physiology , National Cardiovascular Center Research Institute , 5-7-1 Fujishirodai, Suita, Osaka 565-8565 , Japan 2 Department of Cardiovascular Medicine, Graduate School of Medicine , Kobe University , Kobe , Japan

    4 shared publications

Latest Publications

  • Placenta-Derived Extracellular Vesicles From Preeclamptic Pregnancies Impair Vascular Endothelial Function via Lectin-Like Oxidized LDL Receptor-1

    by Roberto Villalobos-Labra, Ricky Liu, Floor Spaans, Tamara Sáez, Tamara Semeria Maitret, Anita Quon, Tatsuya Sawamura, Christy-Lynn M. Cooke, Sandra T. Davidge

    BACKGROUND: Preeclampsia is a complex syndrome that includes maternal vascular dysfunction. Syncytiotrophoblast-derived extracellular vesicles from preeclampsia placentas (preeclampsia-STBEVs) were shown to induce endothelial dysfunction, but an endothelial transmembrane mediator is still unexplored. The LOX-1 (lectin-like oxidized low-density lipoprotein receptor-1) is a transmembrane scavenger receptor that can cause endothelial dysfunction, and its expression is increased in the endothelium of preeclampsia women. In this study, we hypothesized that LOX-1 mediates the effects of preeclampsia-STBEVs on endothelial function. METHODS: Preeclampsia-STBEVs were collected by perfusion of placentas from women with preeclampsia and in vitro and ex vivo endothelial cell function were assessed. RESULTS: In human umbilical vein endothelial cells, inhibition of LOX-1 with LOX-1 blocking antibody (TS20) reduced the uptake of preeclampsia-STBEVs (61.3±8.8%). TS20 prevented the activation of ERK (extracellular signal-regulated kinase, a kinase downstream of LOX-1) and reduced the activation of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells; 21.1±8.0%) and nitrative stress (23.2±10.3%) that was induced by preeclampsia-STBEVs. Vascular function was assessed by wire myography in isolated mesenteric arteries from pregnant rats that were incubated overnight with preeclampsia-STBEVs±TS20. TS20 prevented endothelium-dependent vasodilation impairment induced by preeclampsia-STBEVs. Nitric oxide contribution to the relaxation was reduced by preeclampsia-STBEVs, which was prevented by TS20. Superoxide dismutase or apocynin, an inhibitor of NOX (nicotinamide adenine dinucleotide phosphate oxidase), restored the impaired endothelium-dependent vasodilation in arteries exposed to preeclampsia-STBEVs. CONCLUSIONS: Taken together, our findings demonstrate that LOX-1 mediates the endothelial dysfunction induced by preeclampsia-STBEVs. Our study further expands on the mechanisms that may lead to adverse outcomes in preeclampsia and proposes LOX-1 as a potential target for future interventions.


  • The Scavenger Receptor LOX-1 Limits Immune Reactivity in Alveolar Macrophages

    by F.T. Korkmaz, T. Horace, R. Wallace, M. Perez Vazquez, M. Ozkan, J. Mehta, T. Sawamura, M.R. Jones, K. Traber, J.P. Mizgerd, et al.

  • Open Access

    Lectin-like oxidized low-density lipoprotein receptor 1 attenuates pneumonia-induced lung injury

    by Filiz T. Korkmaz, Anukul T. Shenoy, Elise M. Symer, Lillia A. Baird, Christine V. Odom, Emad I. Arafa, Ernest L. Dimbo, Elim Na, William Molina-Arocho, Matthew Brudner, et al.

    Identifying host factors that contribute to pneumonia incidence and severity are of utmost importance to guiding the development of more effective therapies. Lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1, encoded by OLR1 ) is a scavenger receptor known to promote vascular injury and inflammation, but whether and how LOX-1 functions in the lung are unknown. Here, we provide evidence of substantial accumulation of LOX-1 in the lungs of patients with acute respiratory distress syndrome and in mice with pneumonia. Unlike previously described injurious contributions of LOX-1, we found that LOX-1 is uniquely protective in the pulmonary airspaces, limiting proteinaceous edema and inflammation. We also identified alveolar macrophages and recruited neutrophils as 2 prominent sites of LOX-1 expression in the lungs, whereby macrophages are capable of further induction during pneumonia and neutrophils exhibit a rapid, but heterogenous, elevation of LOX-1 in the infected lung. Blockade of LOX-1 led to dysregulated immune signaling in alveolar macrophages, marked by alterations in activation markers and a concomitant elevation of inflammatory gene networks. However, bone marrow chimeras also suggested a prominent role for neutrophils in LOX-1–mediated lung protection, further supported by LOX-1 + neutrophils exhibiting transcriptional changes consistent with reparative processes. Taken together, this work establishes LOX-1 as a tissue-protective factor in the lungs during pneumonia, possibly mediated by its influence on immune signaling in alveolar macrophages and LOX-1 + airspace neutrophils.


  • NanoSPECT imaging reveals the uptake of 123I-labelled oxidized low-density lipoprotein in the brown adipose tissue of mice via CD36

    by Kento Hosomi, Hidekazu Kawashima, Atsushi Nakano, Akemi Kakino, Yuko Okamatsu-Ogura, Yuki Yamashita, Mai Sasaoka, Daisaku Masuda, Shizuya Yamashita, Chu-Huang Chen, et al.

    The liver is the major organ shown to remove oxidized low-density lipoprotein (oxLDL) from the circulation. Given increased evidence that thermogenic adipose tissue has anti-atherogenic effects, we used 123I-labeled oxLDL as a tracer to reveal oxLDL accumulation in the brown adipose tissue (BAT) of mice. We also explored the mechanisms of oxLDL accumulation in BAT. We used high-resolution nanoSPECT/CT to investigate the tissue distribution of 123I-oxLDL and 123I-LDL (control) following intravenous injection into conscious mice. 123I-oxLDL distribution was discovered in BAT at an intensity equivalent to that in the liver, whereas 123I-LDL was detected mostly in the liver. Consistent with the function of BAT related to sympathetic nerve activity, administering anesthesia in mice almost completely eliminated the accumulation of 123I-oxLDL in BAT, and this effect was reversed by administering β3-agonist. Furthermore, exposing mice to cold stress at 4 °C enhanced 123I-oxLDL accumulation in BAT. Because in 123I-oxLDL, the protein of oxLDL was labeled, we performed additional experiments with DiI-oxLDL in which the lipid phase of oxLDL was fluorescently labeled and observed similar results, suggesting that the whole oxLDL particle was taken up by BAT. To identify the receptor responsible for oxLDL uptake in BAT, we analyzed the expression of known oxLDL receptors (e.g., SR-A, CD36, LOX-1) in cultured brown adipocyte cell line and primary brown adipocytes and found that CD36 was the major receptor expressed. Treatment of cells with CD36 siRNA or CD36 neutralizing antibody significantly inhibited DiI-oxLDL uptake. Finally, CD36 deletion in mice abolished the accumulation of 123I-oxLDL and DiI-oxLDL in BAT, indicating that CD36 is the major receptor for oxLDL in BAT. We show novel evidence for the CD36-mediated accumulation of oxLDL in BAT, suggesting that BAT may exert its anti-atherogenic effects by removing atherogenic LDL from the circulation.


  • Open Access

    Adiponectin forms a complex with atherogenic LDL and inhibits its downstream effects

    by Akemi Kakino, Yoshiko Fujita, Liang-Yin Ke, Hua-Chen Chan, Ming-Hsien Tsai, Chia-Yen Dai, Chu-Huang Chen, Tatsuya Sawamura


  • Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1): a crucial driver of atherosclerotic cardiovascular disease

    by Alexander Akhmedov, Tatsuya Sawamura, Chu-Huang Chen, Simon Kraler, Daria Vdovenko, Thomas F Lüscher

    Cardiovascular diseases (CVDs), specifically lipid-driven atherosclerotic CVDs, remain the number one cause of death worldwide. The lectin-like oxidized low-density lipoprotein (LDL) receptor-1 (LOX-1), a scavenger receptor that promotes endothelial dysfunction by inducing pro-atherogenic signalling and plaque formation via the endothelial uptake of oxidized LDL (oxLDL) and electronegative LDL, contributes to the initiation, progression, and destabilization of atheromatous plaques, eventually leading to the development of myocardial infarction and certain forms of stroke. In addition to its expression in endothelial cells, LOX-1 is expressed in macrophages, cardiomyocytes, fibroblasts, dendritic cells, lymphocytes, and neutrophils, further implicating this receptor in multiple aspects of atherosclerotic plaque formation. LOX-1 holds promise as a novel diagnostic and therapeutic target for certain CVDs; therefore, understanding the molecular structure and function of LOX-1 is of critical importance. In this review, we highlight the latest scientific findings related to LOX-1, its ligands, and their roles in the broad spectrum of CVDs. We describe recent findings from basic research, delineate their translational value, and discuss the potential of LOX-1 as a novel target for the prevention, diagnosis, and treatment of related CVDs.


  • The relationship between serum levels of LOX-1 ligand containing ApoAI as a novel marker of dysfunctional HDL and coronary artery calcification in middle-aged Japanese men

    by Aya Hirata, Akemi Kakino, Tomonori Okamura, Yoko Usami, Yoshiko Fujita, Aya Kadota, Akira Fujiyoshi, Takashi Hisamatsu, Keiko Kondo, Hiroyoshi Segawa, et al.


  • Open Access

    LDL uptake-dependent phosphatidylethanolamine translocation to the cell surface promotes fusion of osteoclast-like cells

    by Victor J. F. Kitano, Yoko Ohyama, Chiyomi Hayashida, Junta Ito, Mari Okayasu, Takuya Sato, Toru Ogasawara, Maki Tsujita, Akemi Kakino, Jun Shimada, et al.

    Osteoporosis is associated with vessel diseases attributed to hyperlipidemia, and bone resorption by multinucleated osteoclasts is related to lipid metabolism. In this study, we generated low-density lipoprotein receptor (LDLR)/lectin-like oxidized LDL receptor-1 (LOX-1) double knockout (dKO) mice. We found that, like LDLR single KO (sKO), LDLR/LOX-1 dKO impaired cell-cell fusion of osteoclast-like cells (OCLs). LDLR/LOX-1 dKO and LDLR sKO preosteoclasts exhibited decreased uptake of LDL. The cell surface cholesterol levels of both LDLR/LOX-1 dKO and LDLR sKO osteoclasts were lower than the levels of wild-type OCLs. Additionally, the amount of phosphatidylethanolamine (PE) on the cell surface was attenuated in LDLR/LOX-1 dKO and LDLR sKO pre-OCLs, while the PE distribution in wild-type OCLs was concentrated on the filopodia in contact with neighboring cells. Abrogation of the ATP binding cassette G1 (ABCG1) transporter, which transfers PE to the cell surface, caused decreased PE translocation to the cell surface and subsequent cell-cell fusion. The findings of this study indicate the involvement of a novel cascade (LDLR∼ABCG1∼PE translocation to cell surface∼cell-cell fusion) in multinucleation of OCLs.


  • Open Access

    Endothelial LOX-1 plays a critical role in inflammatory thrombosis

    by Akemi Kakino, Yoshiko Fujita, Tatsuya Sawamura

    Aim: LOX-1 is implicated in the progression of arteriosclerosis and inflammatory diseases. In this study, we explored whether LOX-1 is involved in inflammation-related thrombosis. Methods: To analyze thrombosis, tail-bleeding time assay was performed using male C57BL/6J (WT) and LOX-1 deficient mice (LOX-1KO). Platelet counts and thrombin-antithrombin complex (TAT) were also measured. To analyze which tissue is responsible in LOX-1-supported thrombosis, tamoxifen-inducible endothelial cell-specific LOX-1KO mice (EC-LOX-1KO) were generated and employed. LOX-1 expression in tissues was analyzed by qRT-PCR. Soluble LOX-1 (sLOX-1) in mouse plasma was measured by ELISA. Results: In normal condition, tail-bleeding time did not show significant difference between WT and LOX-1KO. Under inflammatory condition, in WT, the bleeding time was shortened in LPS injection (5 mg/kg, i.p.) group compared to the control saline group. Consequently, platelet count was decreased, and TAT level was increased in this condition. LOX-1 expression level increased in any tissues examined and plasma sLOX-1 level increased after LPS injection. On the other hand, in LOX-1KO, above LPS-dependent changes were significantly suppressed. Furthermore, EC-LOX-1KO showed similar results to LOX-1KO, suggesting that endothelial LOX-1 plays a crucial role in thrombosis under inflammatory conditions. Conclusions: Endothelial LOX-1 promotes inflammation-related thrombosis, which suggests prothrombotic role of endothelial LOX-1 in atheromatous inflammatory lesion.

  • Open Access

    A Novel Cell-Free, Non-Fluorescent Method to Measure LOX-1-Binding Activity Corresponding to The Functional Activity of HDL

    by Akemi Kakino, Yoko Usami, Sayaka Horiuchi, Yoshiko Fujita, Kazuhiko Kotani, Chu-Huang Chen, Tomonori Okamura, Tatsuya Sawamura

    Aims: A functional abnormality in high-density lipoprotein (HDL) particles rather than a quantitative abnormality in HDL cholesterol levels has been suggested to promote atherosclerosis. The modification of HDL may underlie functional changes to HDL such as gaining the ability to bind and activate the lectin-like oxidized low-density lipoprotein (LDL) receptor-1 (LOX-1). We aimed to develop a novel method for measuring modified HDL on the basis of its binding to LOX-1.Methods: We designed a LOX-1 binding–based enzyme-linked immunosorbent assay (ELISA) with recombinant LOX-1 and anti-apoAI antibody. A lipid-free standard was devised by making a chimeric fusion protein containing anti-LOX-1 antibody and human apoAI fragment. We used this system to detect modified HDL, designated as LOX-1 ligand containing apoAI (LAA).Results: With our ELISA system, we detected HDL modified by copper oxidation, hypochlorous acid, 4-hydroxynonenal, and potassium cyanate, but not native HDL. Upon oxidation, HDL showed increased LOX-1 binding activity and decreased cholesterol efflux and paraoxonase-1 activities. In the ELISA, the chimeric fusion protein standard showed minimal variation in reference binding curves in contrast to copper-oxidized HDL preparations, suggesting better quality control of the chimeric fusion protein as the standard for measuring modified HDL activity. LAA was detectable in the plasma of healthy individuals and of mice fed a high-fat diet.Conclusion: We have developed a novel ELISA by using recombinant LOX-1 and anti-apoAI antibody to measure the activity of modified HDL in plasma.